Catherine Smith, MD, assistant professor, Division of Hematology/Oncology, Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses patient acquired resistance in quizartinib (AC220) and gilteritinib (ASP2215) in acute myeloid leukemia (AML).
Christopher Crane, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the emergence and success of new technologies in the treatment of patients with gastrointestinal (GI) malignancies.
Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the PACIFIC trial for patients with non–small cell lung cancer (NSCLC).
Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the future of immunotherapy for patients with renal cell carcinoma (RCC).
Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses ongoing trials for patients with HER2-positive breast cancer.
Loretta Erhunmwunsee, MD, thoracic surgeon, assistant professor of surgery, City of Hope, discusses the factors that contribute to disparities in the treatment of patients with lung cancer.
Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, explains the case for neoadjuvant therapy in the treatment of kidney cancer.
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the phase II regorafenib (Stivarga) dose optimization study (ReDOS) in metastatic colorectal cancer.
Sandy Wong, MD, assistant professor, University of California, San Francisco School of Medicine, discusses anti-amyloid fibril treatments, a class of agents that have yet to receive FDA approval in the treatment of patients with immunoglobulin light chain amyloidosis (AL amyloidosis).
Alan Skarbnik, MD, staff physician, department of Bone Marrow Transplant, department of Lymphoma, John Theurer Cancer Center, discusses unmet needs for patients with high-risk hematologic malignancies.
Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the background of a study investigating molecular alterations for patients with pancreatic cancer.
Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses the future of treatments for patients with endometrial cancer.
Gabriel Mannis, MD, assistant professor, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the FDA approval and potential approval of 2 new agents that will provide a more nuanced treatment approach for patients with acute myeloid leukemia (AML).
Matthew S. Davids, MD, MMSc, associate director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia, discusses results of a study combining ibrutinib (Imbruiva) plus fludarabine-cyclophosphamide-rituximab (FCR) in patients with chronic lymphoctic leukemia (CLL).
Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the toxicities associated with chimeric antigen receptor (CAR) T-cell therapy.
Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses sacituzumab govitecan (IMMU-132) for the treatment of patients with triple-negative breast cancer.
Diane Reidy Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing clinical trials and recent approvals that will shape the standard of care in the treatment of patients with neuroendocrine tumors (NETs).
Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the role of tucatinib (ONT-380) for patients with HER2-positive breast cancer.
David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses advancements with androgen receptor (AR)-directed therapy for patients with prostate cancer.
Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center, discusses the findings from a study on the incidence and survival impact of self-reported symptom and psychological distress for patients with multiple myeloma.
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the potential approval of cabozantinib (Cabometyx) in hepatocellular carcinoma (HCC) could affect the treatment landscape in liver cancer.
Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses response to the chimeric antigen receptor (CAR) T-cell therapy bb2121 in patients with multiple myeloma.
Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, on considerations for the treatment of patients with HER2-positive breast cancer.
Samir Taneja, MD, James M. Neissa and Janet Riha Neissa professor of urologic oncology, vice chair, Department of Urology, professor, Department of Radiology, co-director, Smilow Comprehensive Prostate Cancer Center, director, Urologic Oncology, Genito-Urologic program leader, NYU Langone’s Perlmutter Cancer Center, discusses multiparametric MRI in prostate cancer.
Malcolm Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses how to determine a treatment strategy for patients with prostate cancer following the 10-year PROTECT study data.
Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the benefits of ibrutinib (Imbruvica) in combination with venetoclax (Venclexta) and obinutuzumab (Gazyva) for patients with chronic lymphocytic leukemia (CLL).
Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discuss the efficacy of selinexor in combination with dexamethasone for the treatment of patients with multiple myeloma.
Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the importance of molecular markers in lung cancer.
Alicia Morgan, MD, Mather Hospital, discusses the impact of PARP inhibitors in prostate cancer.
Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses the future of immunotherapy in gastrointestinal stromal tumors (GIST).